China Cracks Down On Device Clinical Data Forgery, Problematic Manufacturing
This article was originally published in PharmAsia News
Drawing success from a recent compliance campaign targeting drug makers in China, CFDA is now clamping down on the medical device industry, underscoring concerns over frequent violations and quality issues amid the sector’s fast growth.
You may also be interested in...
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.